Introduction
Inter-individual variability in xenobiotic and drug metabolism is extensive. Plasma levels of a drug can vary more than 1000-fold between individuals upon the same drug dosage. 1 These variations can be caused by induction or inhibition and genetic polymorphisms of metabolizing enzymes, or from physiological, pathophysiological or environmental factors. 2 In fact, genetic factors are considered to be responsible for 20-40% of the differences between individuals in the response and susceptibility to drugs and xenobiotics. 3 Variability among individuals in drug metabolism can result in reduced drug efficacies or undesirable toxic side effects, which are phenomena that may compromise drug therapy and development.
Cytochrome P450s (CYPs) are responsible for the metabolism of a wide variety of clinically, physiologically and toxicologically important compounds. 4 CYP families 1, 2 and 3 are responsible for 70-80% of all phase I metabolism of clinically used drugs 5 and are involved in the biotransformation of a large number of xenobiotics. Biotransformation can lead to bioactivation of pre-carcinogens and drugs, which can result in carcinogenic or other toxic effects. The majority of CYP-mediated xenobiotic metabolism is carried out by polymorphic enzymes. 6 Human CYP polymorphisms include mutations both in non-coding regions (promoter, intron) and protein-coding sequences. Mutations in noncoding regions may lead to altered expression levels, whereas those in protein-coding sequences may change the structure and catalytic properties of the enzyme. 7 Many drugs that can cause adverse reactions are metabolized in processes catalyzed by polymorphic CYP enzymes. Therefore, the understanding of the nature of CYP polymorphisms is fundamental for the comprehension of interindividual differences in chemical exposure, adverse drug effects and toxicity in general. 8 The human CYP1A family consists of CYP1A1 and CYP1A2. Their genes are located on chromosome 15 and are oriented head-to-head, 23.3 kb apart. 9 The spacer sequence may contain distinct regulatory regions of each gene or, alternatively, the regulatory regions of both genes. 10 CYP1A1 is mainly expressed in extrahepatic tissues, whereas CYP1A2 is almost exclusively expressed in the liver, representing B15% of its total CYP content.
11 CYP1A enzymes catalyze the bioactivation of pre-carcinogens, such as polycyclic aromatic hydrocarbons (CYP1A1), as well as aromatic and heterocyclic amines (CYP1A2).
12 CYP1A2 is also responsible for the metabolism of drugs, such as phenacetin, 13 clozapine, 14, 15 naproxen, 16 propranolol 17 and tizanidine. 18 The CYP1A2 gene consists of seven exons, including noncoding exon 1. 19 Inter-individual differences in CYP1A2 activity are well known; up to 60-fold variations have been reported. 11, 20 In addition, B15-and 40-fold variations in mRNA and protein expression levels have been observed in the human liver. 19, 21 To date, 36 CYP1A2 haplotypes have been published on the Human Cytochrome P450 Allele Nomenclature Committee home page (http://www.cypalleles. ki.se/cyp1a2.htm). Of these, 21 are in the non-coding region and 15 are in the coding region, all causing amino-acid changes of the CYP1A2 protein. Apart from studies that characterized gene polymorphisms in the non-coding region, few reports described non-synonymous protein polymorphisms. Mostly, these concern the identification of genetic polymorphisms and their frequencies, but not their effects on protein level and activities. Murayama et al., 22 Saito et al. 23 and Zhou et al. 7 characterized most of the non-synonymous polymorphisms with a limited number of substrates. The primary objective of this study is to investigate polymorphic forms, representing the majority of alleles with the non-synonymous polymorphic CYP1A2 protein, and to characterize their activity with a diverse group of substrates.
On the basis of a crystal structure published by Sansen et al. 24 of CYP1A2 wild-type (WT) (CYP1A2*1), we selected mutants that seemed to be localized in the vicinity of the active center, heme, entrance/exit channel or the NADPH cytochrome P450 oxidoreductase (CYPOR) interaction zone. As such, these polymorphic forms concern T83M (CYP1A2*9), S212C (CYP1A2*12), S298R (no allele designation), G299S (CYP1A2*13), I314V (no allele designation), I386F (CYP1A2*4), C406Y (CYP1A2*5) and R456H (CYP1A2*8). For this purpose, the cDNA of the WT allele, present in a bacterial expression vector, 25 was adapted through genetic engineering to generate the eight different CYP1A2 forms. CYP1A2 alleles were coexpressed with human CYPOR in a bacterial cell model, 26 and the activity of the eight allelic variants and WT was investigated. The enzyme activity of these variants was analyzed together with WT and scrutinized through multivariate analysis. Results of this analysis were interpreted using the CYP1A2 crystal structure. 24 
Materials and methods
Reagents L-arginine, ampicillin, kanamycin sulfate, chloramphenicol, cytochrome c, isopropyl b-D-thiogalactoside (dioxane-free), thiamine, 2-aminoanthracene (2AA), glucose-6-phosphate, NADPH, ethoxyresorufin (ER), methoxyresorufin (MR), resorufin (R), phenylmethanesulfonyl fluoride and a-naphthoflavone (a-NF) were obtained from Sigma Chemical (St Louis, MO, USA). 2-Amino-3-methylimidazo(4,5-f)quinoline (IQ) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) were obtained from Toronto Research Chemicals (North York, ON, Canada). Both 3-cyano-7-ethoxycoumarin (CEC) and 3-cyano-7-hydroxycoumarin (CHC) were obtained from BD Biosciences (Bedford, MA, USA). Phenacetin was obtained from Brocades-ACF (Maarssen, The Netherlands) and clozapine from Duchefa Farma bv. (Haarlem, The Netherlands). Bacto agar, bacto peptone, bacto tryptone and bacto yeast extract were obtained from Difco (Detroit, MI, USA). All other chemicals were of the highest quality.
Site-directed mutagenesis Site-directed mutagenesis was performed using 'Quickchange XL' (Cedar Creek, TX, USA) and applied according to the manufacture's instructions. All variants, except I386F, were constructed using plasmid pCWh1A2 26 as DNA template, encoding human CYP1A2*1 (isoform 2) (NCBI NM_000761) with the N terminus modified as described by Fisher et al. 25 In the case of the variant I386F, the template was pUC18_h1A2. This plasmid was constructed by cloning the cDNA of CYP1A2 from pCWh1A2 as an NdeI-XbaI fragment in pUC18. Forward and reverse mutagenesis primers for the creation of the desired mutation for each variant are presented in Supplementary Table 1 .
The introduced mutation for each variant was confirmed by sequencing the full extent of the CYP1A2 cDNA. The pCWh1A2 plasmid has a considerable size (6.9 kb), and it is known that, for a site-directed mutagenesis procedure, large plasmids have a reduced but significant risk for incorporation of undesired mutations. Therefore, mutated cDNAs were re-cloned into the pCW vector to ensure that plasmid sequences remained unaltered. For this, the restriction sites NdeI and XbaI were used, and the cDNA was subsequently resequenced.
Bacterial coexpression of CYP1A2 variants with CYPOR and membrane preparation The expression of the different variants of CYP1A2 with CYPOR was obtained as described previously, using the bi-plasmid coexpression system. 26 Briefly, each strain was cultured in the TB (Terrific Broth) medium supplemented with peptone (2 g l À1 ), thiamine (1 mg ml À1 ), ampicillin (50 mg ml À1 ), kanamycin (15 mg ml À1 ), chloramphenicol (10 mg ml À1 ), trace elements solution 27 (4 ml ml À1 ) and 0.2 mM of isopropyl b-D-thiogalactoside (dioxane-free) (final concentrations). Cultures were started with 250 ml of À80 1C glycerol stocks, and cells were grown for 16 h at 28 1C with moderate agitation.
Membrane preparations were isolated as follows. Cultures were harvested at 2772 Â g for 20 min at 4 1C. The pellet was resuspended in TS (Tris-sucrose) buffer (75 mM Tris-HCl, 250 mM sucrose, pH 7.8). Lysozyme was added to a final concentration of 0.5 mg ml À1 , and cells were incubated on a roller bench for 30 min at 4 1C. Subsequently, EDTA (0.5 mM) and the protease inhibitor phenylmethanesulfonyl fluoride (0.5 mM) were added. Cell lyses was performed by freezing (À80 1C) and thawing (1 cycle) and by subsequent several short rounds (60 s) of low-intensity sonication, interspersed with 30 s of ice-bath submersion, such that the temperature of the preparation never exceeded 8 1C. The suspension was centrifuged at 2772 Â g, for 10 min at 4 1C to eliminate unbroken cells. Membranes were pelleted by ultracentrifugation of the supernatant at 100 000 Â g at 4 1C for 60 min. Membranes were resuspended in TGE buffer (75 mM TrisHCl, 10% (v/v) glycerol, 25 mM EDTA, pH 7.5) using a Dounce homogenizer, Jencons PLS (East Sussex, UK) and stored at À80 1C. In the case of phenacetin and clozapine experiments, membranes were obtained from cells, which had been lysed by French Press (3 cycles at 1000 psi on ice) and a subsequent sonication treatment (2 cycles of 2 min). Protein concentrations were determined using the method described by Bradford, following the manufacturer's protocol from Bio-Rad (San Francisco, CA, USA), using bovine serum albumin as the standard.
The CYP content of whole cells and membrane preparations, was determined using the CO-difference spectra technique as described previously. 28 The CYPOR content of membrane preparations was determined using the NADPH-cytochrome c reduction assay as described previously. 29 Western blot analysis Membrane proteins (10 mg) were separated by SDS-PAGE electrophoresis (10%) and electrotransferred onto nitrocellulose membranes Hybond-ECL from GE Healthcare (Uppsala, Sweden). Immunoblotting analyses were carried out with the enhanced chemiluminescent ECL western blotting detection kit from GE Healthcare, using as primary antibody a polyclonal antibody from rabbit serum raised against recombinant human CYP1A2 from CYPEX (Dundee, UK).
7-Methoxy-and 7-ethoxy-resorufin O-dealkylation 7-Methoxy-(MROD) and 7-ethoxy-resorufin (EROD) O-dealkylation activities were performed in a 96-well microplate format, as described by Kranendonk et al. 29 using a Zenyth 3100 microplate reader from Anthos (Imola, Italy). All measurements were carried out in triplicate and were performed at least three times in separate experiments. Stock solutions of MR and ER were prepared in dimethyl sulfoxide and were varied over eight concentrations (MR: p2 mM; ER: p5 mM), maintaining a constant final solvent concentration of 0.2% (v/v) throughout the experiment, thus preventing interference with CYP1A2 activity. 30 The reactions were followed for the first 15 min. Velocity data were plotted according to the Michaelis-Menten equation, and kinetic parameters (V max and K M ) were calculated using GraphPad Prism from GraphPad software (La Jolla, CA, USA) applying one binding site analysis (hyperbola).
3-Cyano-7-ethoxycoumarin O-dealkylation
The 3-cyano-7-ethoxycoumarin O-dealkylation (CECOD) activity was measured as the rate of the increase in CHC (excision: 409 nm; emission: 460 nm). All measurements were carried out in triplicate and were performed at least three times in separate experiments, in a 96-well microplate format using a Zenyth 3100 microplate reader. Rates (mM CHC formed per min) could be calculated using a fluorescence standard curve of the product CHC. The reaction was performed with membranes (1 pmol of CYP1A2 per well) under the same conditions as for EROD and MROD. Stock solutions of CEC were prepared in acetonitrile and were varied over eight concentrations (p75 mM), maintaining a constant final solvent concentration of 0.2% (v/v) throughout the experiment. The reactions were followed for the first 15 min. Velocity data were plotted according to the Michaelis-Menten equation, and kinetic parameters (V max and K M ) were calculated using GraphPad prism software, applying one binding site analysis (hyperbola).
Inhibition studies IC 50 determinations for a-NF were performed for MROD, EROD and CECOD as described above. In all, 12 different a-NF concentrations (p5 mM) were used for each substrate. Substrate concentrations were 1.0, 2.5 and 25.0 mM for MR, ER and CEC, respectively.
The activity for each inhibitor concentration was determined at least in triplicate. IC 50 was calculated with the GraphPad prism software using sigmoidal dose-response analysis.
Clozapine N-demethylation Clozapine N-demethylation activity was measured as the rate of the increase in demethylated clozapine absorbance at 254 nm using high-performance liquid chromatography (HPLC) coupled with a Separations 759A absorbance detector from Applied Biosystems (Foster City, CA, USA). All measurements were performed in triplicate and at least three times in separate experiments. Rates (pmol demethylated clozapine formed per min) were estimated using a standard curve of the substrate (clozapine), assuming that the extinction coefficients of the substrate and metabolite (demethylated clozapine) are comparable. 31 To verify Michaelis-Menten characteristics (that is, time, substrate and enzyme dependence) of the metabolism of clozapine by CYP1A2, a full kinetic analysis with WT was performed. For this purpose, 100 nM of CYP1A2 was used per incubation and a gradient of 7 clozapine concentrations (p500 mM). Analysis of clozapine demethylation by the 8 polymorphic CYP1A2 forms was performed with 100 nM of enzyme and 50 and 250 mM of clozapine. All incubations were performed in a final volume of 300 ml, and incubated for 60 min at 37 1C. Reactions were initiated by adding 3.3 mM NADPH and terminated with 30 ml of 10% (v/v) HClO 4 . The precipitated protein was removed by centrifugation (for 15 min at 4000 Â g), and the supernatant was analyzed by HPLC. Metabolites were separated using a C18 Luna 5-U 100A column from Phenomenex (Torrance, CA, USA) at a flow rate of 0.6 ml min À1 . A gradient program was applied, using two mobile-phase solutions: A contained 99% H 2 O, 1% acetonitrile and 0.02% formic acid and B contained 99% acetonitrile, 1% H 2 O and 0.02% formic acid. The separation was initiated with 100% A and maintained for 5 min. Subsequently, solution B was increased linearly to reach 100% after 30 min and the percentage of solution B was inversed to 0% in 5 min.
Phenacetin O-deethylation Phenacetin O-deethylation activity was measured as the rate of the increase in acetaminophen absorbance at 254 nm by HPLC analysis using a Separations 759A absorbance detector. All measurements were performed in triplicate and at least three times in separate experiments. Rates (pmol acetaminophen formed per min) could be calculated by using a standard curve of the product acetaminophen.
To verify Michaelis-Menten characteristics (time, substrate and enzyme dependence) of the metabolism of phenacetin by CYP1A2, a full kinetic analysis with WT was performed. For this purpose, 100 nM of CYP1A2 was used per incubation and a gradient of 7 phenacetin concentrations (p400 mM). Analysis of phenacetin deethylation by the 8 polymorphic CYP1A2 forms was performed with 100 nM of enzyme and 20 and 200 mM of phenacetin. Incubations and HPLC analysis were performed as for clozapine.
Bioactivation assays
The bioactivation/mutagenicity assays were performed using the liquid pre-incubation assay technique, as described previously. 32 Experiments were performed in triplicate and at least three times in separate experiments. Revertant colonies were counted after 48 h of incubation at 371C. Plates were digitally photographed, and the number of L-arginine prototrophic revertant colonies per plate were determined using Labworks Software (version 4.6) from UVP (Upland, CA, USA). Mutagenic activities (in revertants per nmol or revertants per mmol) were determined from the slope of the linear portion of the dose-response curve.
Multivariate statistical analysis
The normalization procedure was based on the variance in the data set. Both column and row variances were applied. This type of double normalization is appropriate when different enzyme preparations are being compared (that is, using partially purified or subcellular fractions) and when different types of substrates and detection methods are used. 33 Data pre-processing was carried out by dividing the values of the initial data set by the row-column double variance:
Differences between polymorphic variants and WT were analyzed globally by principal component analysis 34 and multidimensional scaling (MDS). 35 
Results
Site-directed mutagenesis, mutant enzyme expression and characterization The eight polymorphic variants of human CYP1A2 were constructed and expressed in Escherichia coli. A suitable E. coli host, the BTC strain, was applied for adequate coexpression of CYP1A2 allelic variants with human CYPOR, using a bi-plasmid system. 26 CYPOR expression levels were determined in the membrane protein fraction and were comparable among all strains (7.9-11.4 pmol mg À1 membrane protein). The CYPOR/CYP ratios for the different variants were found in the range of the normal values as observed in human liver microsomes (0.08-0.5) 36 except for variants I386F and R456H, which had no detectable CYP holoenzyme.
Immunoblot analysis of membrane preparations indicated that CYP-protein expression levels were similar for WT and all eight constructed variants (Supplementary Figure S1) . The CO-difference spectra of all recombinant CYPs expressed in E. coli BTC were also determined to quantify the CYP1A2 holoenzyme content (Supplementary Figure S2) . Holoprotein levels for most variants were comparable with or slightly lower than WT, except for variants I386F and R456H. I386F showed a strongly reduced 450-nm peak and a large 420-nm peak in bacterial cells (Supplementary Figure S2) , and a total absence of the 450-nm peak in membrane fractions (data not shown). This indicates instability of the I386F holoprotein, probably due to inefficient heme incorporation and/or anchoring as a stable apoprotein has been demonstrated by immunodetection (Supplementary Figure S1) . For R456H, no 450-nm peak was detectable in either whole cells or membrane preparations, indicating the absence of holoprotein.
WT and mutant CYP1A2 activities
To determine enzyme activities, all allelic variants were studied using eight structural different substrates and were compared with WT ( Figure 1 ). Three fluorogenic CYP1A2 substrates (ER, MR and CEC), and two therapeutic drugs (clozapine and phenacetin) were used. Furthermore, the bioactivation of three CYP1A2 dependent pre-mutagens (NNK, 2AA and IQ) was measured. All results are summarized in Table 1 .
Kinetic studies with fluorogenic substrates
The polymorphic variants and WT were tested with three typical CYP1A2 fluorogenic substrates (ER, MR and CEC). The results of the Michaelis-Menten kinetic studies (yielding V max and K M values) and the inhibitory potency (IC 50 ) of a-NF, a specific CYP1A inhibitor, are presented in Table 1 . For I386F and R456H, lacking detectable CO-difference spectra, no activity was detected for any of the three substrates, not even at a double membrane sample concentration and at the highest substrate concentration. Therefore, these two variants were excluded from the remaining analysis.
Although, K cat (V max /K M ) is considered to be a valid kinetic descriptor, subtle but significant differences in K M or V max can be obscured. As such, K M and V max were brought forward separately. Variants T83M and I314V showed a small increase in V max compared with WT, for the three substrates. In addition, the affinity for these substrates was altered, except for CEC, with K M values being slightly higher for MR and ER. Variant S298R demonstrated a small decrease in V max both for MROD and EROD, whereas the CECOD activity was comparable with WT. Variants G299S and C406Y showed higher values for V max of MROD, but not for EROD and CECOD. Affinity of variants S298R and G299S for all substrates was found similar to WT, with K M values being comparable with WT. In the case of C406Y, the observed substrate affinities were comparable with WT for CECOD but not for MROD and EROD, with K M values being higher in both cases. Finally, variant S212C showed activities almost identical to WT, for the three fluorogenic substrates, all V max and K M values being comparable with WT.
Kinetic studies with clozapine and phenacetin Both clozapine N-demethylation and phenacetin O-deethylation activities of CYP1A2 variants were also determined. I386F and R456H showed no activity for any of the two substrates, even at the highest substrate and double membrane concentrations. Therefore, these two variants were excluded from the remainder of the analysis. On the basis of the kinetic analysis of WT, two substrate concentrations were chosen. The six remaining variants and WT were incubated with 50 and 250 mM of clozapine (Table 1 and Supplementary Figure S3) , and 20 and 200 mM of phenacetin (Table 1 and Supplementary Figure S4) . Control assays were performed with the highest concentration of each substrate in the presence of 1 mM of the CYP1A2 inhibitor a-NF.
At 20 mM concentration of clozapine, a decreased N-demethylation activity for all variants was found when compared with WT, but this was not the case at a clozapine concentration of 200 mM. At a clozapine concentration of 20 mM, variants T83M, S212C, S298R, G299S, I314V and C406Y showed reaction velocities of 64, 74, 58, 72, 65 and 44% of WT, respectively. At a clozapine concentration of 200 mM, for T83M, S212C, S298R, G299S and C406Y reaction velocities of 83, 89, 108, 112, and 80%, respectively, of the WT activity were obtained, and for the I314V variant 65%.
At low substrate concentrations (50 mM), phenacetin O-deethylation activity was not significantly different for variants T83M, S212C and I314V, being 79, 85 and 97%, respectively, of the WT activity, but was significantly decreased for S298R, G299S and C406Y, being 57, 64 and 48%, respectively, of the WT activity. At a phenacetin Figure 1 Chemical structures of used substrates demonstrating the full structure space of CYP1A2 compounds applied in this study. concentration of 250 mM, the lowest activity found was for variant S298R with 60% of the WT activity, whereas no significant differences in reaction velocities were observed for T83M, S212C, G299S, I314V and C406Y, being 117, 106, 88, 104 and 83%, respectively, of the WT activity. In the case of mutant C406Y, extra peaks on the HPLC chromatogram were observed, which increased along with phenacetin concentration, but disappeared when inhibited with a-NF, indicating a different metabolic profile for this variant (data not shown).
Bioactivation of pre-mutagens Strain BTC1A2, coexpressing recombinant human CYP1A2 and human CYPOR, have previously been shown to correctly bioactivate several known CYP1A2-dependent mutagens. 26 The present polymorphic CYP1A2 variants were further characterized with this cell model. Three premutagens (2AA, NNK and IQ) were used for this purpose (Table 1 and Supplementary Figures S5-S8 ). No mutagenic activity was observed with the CYP1A2 null strain for these three pre-mutagens.
When compared with WT, variants S212C and I314V showed a slight increase in mutagenic activity for 2AA, whereas variants T83M, S298R, G299S and C406Y showed a decrease in mutagenicity. For I314V, the results were comparable with WT. In the case of IQ, variants T83M, S298R, G299S and I314V showed a small decrease in mutagenicity, whereas variants S212C and C406Y were comparable with WT. For NNK, the differences were the most striking as, although variant S298R showed a similar mutagenic activity compared with WT, all other variants had a reduced capacity to bioactivate this mutagen. Remarkably, in the case of T83M and C406Y, no mutagenicity could be detected.
I386F and R456H, two variants with perturbed expression of holoenzyme, showed no mutagenic activity for any of the three pre-mutagens, except for I386F with 2AA being significantly lower than WT.
Multivariate analysis of data
To compare all obtained experimental data, a multivariate analysis was performed. The polymorphic CYP1A2 variants were numbered from 2 to 7, whereas variants I386F and R456H were not included in the analysis. The different parameters, such as V max , K M , relative reaction velocities, IC 50 and mutagenic activities, were designated A to P (Table 1) .
Principal component analysis
Principal component analysis (PCA), a procedure that transforms a high number of possibly correlated variables into a reduced number of uncorrelated variables denominated by principal components, was used to project present date from a 16-dimensional (activity parameters) space into a 2-dimensional space for ease of visualization (Figure 2) . After a twovariance normalization, the first analysis was by a Scree plot analysis (not shown). This analysis indicated that the first principal component retains 94.5% of the initial variance; therefore, this single principal component explains almost all significant variations in the data. The PCA analysis itself seems to indicate that the trend of variation that governs our data set stems from the difference between all WT-like enzymes (WT, no. 3 (S212C), no. 4 (S298R), no. 6 (I314V) and no. 7 (C406Y)), and non-WT-like enzymes (variant no. 5 (G299S) and variant no. 2 (T83M)), as shown in Figure 2 .
Multidimensional scaling
For our data set, two different multidimensional scaling (MDS) configuration plots were constructed. In the first MDS configuration plot, CYP1A2 variants were compared using all activity parameters (Figure 3a) . This plot shows how the enzymes were similar/dissimilar for all assayed activities. Kruskal's stress value was 0.002. The dendrogram depicted in Figure 3b deduced from MDS distances, showed that variants no. 2 (T83M) and no. 4 (S298R) were very similar and both were found slightly different from WT and variants no. 3, no. 6 and no. 7 (S212C, I314V and C406Y). Variant no. 5 (G299S) appears, again like in the PCA analysis, to constitute itself a particular enzyme, and different from all the others.
The second MDS configuration plot depicted in Figure 4 compares the different activity parameters for the assayed CYP1A2 enzymes. This plot shows the force of activities in scrutinizing between the different CYP1A2 enzymes. Kruskal's stress value was 0.207, slightly over the typical value of 0.15; however, we are confident that this plot is meaningful. Three clusters could be deduced from the MDS configuration plot, which shows the distances between the activities for all assayed enzymes. Two objects were located in very separate and opposite areas of the graph, namely parameter C (EROD V max ) and parameter M (NNK mutagenic activity). All other parameters aggregated together in the central area of the two-dimensional plot.
Discussion
Polymorphisms in xenobiotic-metabolizing enzymes have been recognized as a main factor in inter-individual variability in drug and xenobiotic responses and susceptibilities. In particular, CYP1A2 is involved in the metabolism of a large number of drugs and chemical carcinogens. A recent study found significant differences in CYP1A2 activity between ethnic groups (Swedes and Koreans), not related to environmental factors. 37 CYP1A2 polymorphisms could also be related to the toxicity of leflunomide in patients with rheumatoid arthritis 38 and seem to have a role in the efficacy of treatment of patients with antipsychotics, such as clozapine and olanzepine. 39 Several studies indicated implications of CYP1A2 polymorphisms in cancer susceptibility, namely for pancreatic cancer 40 and bladder cancer. 41 To date, 39 single-nucleotide polymorphisms of human CYP1A2 have been reported (from which 36 haplotypes were determined), describing alterations on DNA sequence levels and in some cases their epidemiological frequencies. From the 17 known non-synonymous protein polymorphic alleles, 5 have not been characterized regarding their enzymatic activity (S212C, F21L, S298R, I314V and R431W; see Table 2 ). Two of these were included in this study. Formerly, other non-synonymous protein forms were probed with only two substrates, except for I386, D348W and C406, which were analyzed with more substrates (see Table 2 ). In this report, we describe the thorough characterization of 8 polymorphic variants of human CYP1A2, with 16 different activity parameters. The CYP content was similar to WT for all variants, except for I386F and R456H. These variants showed severely reduced or absent holoenzyme, respectively, in bacterial cells, and both were absent in membrane fractions, indicating highly unstable holoenzymes. The CYPOR expression levels in membrane preparations when coexpressed with the various CYP1A2 variants were similar to the WT strain. The CYPOR/CYP stoichiometry is recognized as a critical factor for the catalytic properties of CYP enzymatic system. 26 CYPOR/CYP ratios for the different variants were found to be in the range of those observed in human liver microsomes. These results first indicated that coexpression of these CYP1A2 variants with CYPOR represented an adequate approximation of the in vivo situation, and second that in principle the observed alterations in CYP1A2 activity could be solely ascribed to the CYP1A2 variant.
CYP1A2 variants were subjected to several activity assays using eight substantially different substrates, in an attempt to discriminate between allelic variants as much as possible. Different substrate classes with different types of CYP1A2-mediated reactions were used, namely O-dealkylation (MR, ER, CEC and phenacetin), N-demethylation (clozapine) and N-hydroxylation (NNK, IQ and 2AA).
As a result, a very heterogeneous activity data set could be generated for CYP1A2 allelic forms. To thoroughly analyze this diverse data set, multivariate statistical analysis, a very useful statistical tool, was performed on this data set. Variants I386F and R456H were excluded from this analysis because of the lack of detectable holoenzyme. Differences between polymorphic CYP1A2 variants and WT were analyzed globally by principal component analysis and multidimensional scaling, two statistical tools of complementary interest as was shown in several fields, 42, 43 including the recent exploration of protein structure space. 44, 45 All applied statistical analyses indicated that variant S212C (no. 3) represents the most similar enzyme to WT. Murayama et al. 22 found similar relative activities to WT for this variant, using two substrates, namely ER and phenacetin. Both PCA and MDS analyses indicate that variants I314V (no. 6) and C406Y (no. 7) are similar to WT. In a previous report, 7 no major differences were observed for variant C406Y activity, corroborating our results. It is interesting to note that the lack of bioactivation of NNK of this variant described in this report coincides with observations from previously referred authors. This group described altered catalytic specificity of C406Y for three heterocyclic amine pre-mutagens, other than NNK. They proposed that possible changes in the regioselectivity and regiospecificity of the reactions might have lead to an altered metabolite profile. This theory seems to be reinforced by our observation of extra metabolites in phenacetin O-dealkylation for this variant. Variant S298R (no. 4) appears to be a slightly different enzyme from WT, both from MDS and PCA analysis. This variant is located on the surface of the heme domain, on the proximal side of the heme (see Figure 5 ). On the basis of alignment and superposition of the human CYP1A2 crystal structure, 24 with the structure of the CYP BM3 heme and FMN-binding domains, 46 S298 also seems to be located near the CYPOR interaction area. The S298R amino-acid change might influence the interaction of CYP1A2 with its redox partner, explaining the observed differences. Both MDS and PCA analysis indicated that variant T83M (no. 2) is a significantly different enzyme from WT. On the basis of the human CYP1A2 structure published by Sansen et al., 24 and the description of substrate entrance and product exit channels of CYPs by Cojocaru et al., 47 it seems likely that this residue is located in a substrate entrance/product exit channel. Finally, G299S (no. 5) is definitely indicated as the most distinguishable variant, of all studied variants in this study. This is consistent with all performed statistical analyses, and it seems to indicate not only a significant different behavior from WT but also from all other analyzed variants. G299 is located beside S298, with the possibility of G299S disturbing the interaction of CYP1A2 with CYPOR (vide supra). From the MDS plot for substrates (Figure 4) , it is interesting to note that NNK (mutagenic activity) represents the most discriminative activity parameter among the CYP1A2 variants of a heterogeneous set of 16 activity parameters.
Variants I386F and R456H showed to be two particular cases, both showing severe problems with holoprotein stability. In a previous study by Zhou et al., 7 variant I386F showed a relative low expression level of holoenzyme when expressed in bacterial cells. The I386 residue is located in the substrate recognition site 5 and based on the CYP1A2 crystal Figure 5 Localization of altered amino acids of the selected CYP1A2 polymorphic variants using the human CYP1A2 crystal structure published by Sansen, et al. 24 (This figure was generated using PDB file no. 2H14).
structure published by Sansen et al., 24 very close to the catalytic center, only 3.8 Å apart from the cocrystallized substrate a-NF and around 4 Å from the heme. In mammalian CYP structures, known up to now, the common structural features of the heme surroundings is formed by the I-helix, the substrate recognition site 5 and the BC loop. 48 The I386F substitution represents the replacement of an aliphatic side chain with an aromatic side chain, which could distort the heme-anchoring structure, explaining the observed highly unstable I386F holoprotein. This is supported by the increase in the 420-nm peak in the COdifference spectrum of this variant, indicating dislocated heme positioning. In the case of R456H, there was no detectable holoenzyme, both in whole cells and membrane fractions, with a concomitant increase in the 420-nm peak in the CO-difference spectrum, observations in accordance with previous study by Saito et al. 23 Previous studies with the rat orthologous of CYP1A2, suggested that the region containing this amino acid is crucial in heme binding and its interaction with CYPOR. 49, 50 The substitution of R456 in humans (corresponding to rat R454) showed markedly reduced activities. In addition, a positively charged residue, the position of which is variable in the C-terminal end of the substrate recognition site 5, has been identified by protein sequence alignments and is conserved in 97.7% of a total of 6379 CYP sequences. 48 The location of this residue in all-known crystal CYP structures, including the CYP1A2 structure indicates that this residue interacts with the 7 0 -propionate of the heme. A previous reported work, which compared four CYP crystal structures and 200 sequences, suggested a functional conserved heme interacting arginine that is also involved in the elimination of water from the active site. 51 In summary, we successfully expressed eight allelic variants of CYP1A2 with human CYPOR and could measure multiple activities parameters of eight structural different substrates. Two of these variants, namely I386F and R456H, were enzymatically inactive. The collected heterogeneous data set from the remaining variants was analyzed using several multivariate analysis tools. This analysis indicated that variant G299S (no. 5) seems to have substantial altered catalytic properties in comparison with WT, whereas variant T83M (no. 2) is slightly but significantly different from the WT. Moreover, an important residue of the scaffold for proper heme binding and stabilization, R456, could be identified in CYP1A2.
At present, it is acknowledged that polymorphisms in CYP1A2 do not profoundly penetrate into the phenotype level. 52 However, we have shown in this study that although the eight variants cause, seemingly on the whole, relatively minor activity changes (besides I386F and R456H), some variants can have profound effects on particular CYP1A2-mediated biotransformation, as was demonstrated for the bioactivation of NNK. As such, the results indicated that several of the studied allelic forms can have pharmokinetic and/or toxicokinetic consequences. Moreover, our results seem to indicate and/or confirm structural characteristics and features of the CYP1A2 enzyme. As such, studying polymorphic CYP activity is also a driving tool for improving our knowledge on the molecular mechanism of the functioning of the human CYP1A2 and the CYP enzyme complex in general.
